Symptomatic Sinus Bradycardia in a Patient with Solitary Fibrous Tumor/Hemangiopericytoma Treated with Pazopanib
Open Access
- 15 September 2021
- journal article
- research article
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 60 (18), 2973-2977
- https://doi.org/10.2169/internalmedicine.5347-20
Abstract
Pazopanib, a multi-targeted tyrosine kinase inhibitor, is associated with cardiovascular adverse events, such as hypertension, cardiac dysfunction, and thromboembolism. However, symptomatic pazopanib-related bradycardia is uncommon. We herein report a case of symptomatic bradycardia of 35 beats per minute in a patient with solitary fibrous tumor/hemangiopericytoma (SFT/HPC) treated with pazopanib for 1 month. His heart rate recovered to a normal range soon after pazopanib cessation. He restarted pazopanib at a reduced dose, which was continued without SFT/HPC progression or bradycardia recurrence. This case highlights the possibility of bradycardia induced by pazopanib and the importance of monitoring the patient's heart rate.Keywords
This publication has 13 references indexed in Scilit:
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large‐scale multinational trials (PROFILE 1005 and 1007)Cancer Medicine, 2016
- Successful use of pazopanib for treatment of refractory metastatic hemangiopericytomaClinical Sarcoma Research, 2014
- Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072Annals of Oncology, 2014
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2012
- Effects of Novel Angiogenesis Inhibitors for the Treatment of Cancer on the Cardiovascular SystemJournal of the American College of Cardiology, 2011
- Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumorCancer, 2011
- (Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis InhibitorThe Oncologist, 2010
- Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)Journal of Clinical Oncology, 2009
- HEMANGIOPERICYTOMA A VASCULAR TUMOR FEATURING ZIMMERMANNʼS PERICYTESAnnals of Surgery, 1942